Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021163456 - T CELL EPITOPES AND RELATED COMPOSITIONS USEFUL IN THE PREVENTION, DIAGNOSIS, AND TREATMENT OF COVID-19

Publication Number WO/2021/163456
Publication Date 19.08.2021
International Application No. PCT/US2021/017825
International Filing Date 12.02.2021
IPC
A61K 39/215 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
A61P 11/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11Drugs for disorders of the respiratory system
A61P 31/14 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
C07K 14/165 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
CPC
A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
A61P 11/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11Drugs for disorders of the respiratory system
A61P 31/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
C07K 14/52
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
52Cytokines; Lymphokines; Interferons
C12N 2770/20022
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2770ssRNA Viruses positive-sense
00011ssRNA Viruses positive-sense
20011Coronaviridae
20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Applicants
  • EPIVAX, INC. [US]/[US]
Inventors
  • DE GROOT, Anne
  • MARTIN, William D.
Agents
  • SCHABOWSKY, Richard Henry
  • THARP, Amy M.
  • BEYER, James E.
  • CAMPBELL, Quinten M.
  • LUNN, Jennifer H.
  • MCNEELY, Richard J.
  • MEYER, Christopher I.
  • MOLLOY, Matthew A.
  • POWELL, Carolyn S.
  • REED, John D.
Priority Data
62/976,71514.02.2020US
62/983,01228.02.2020US
62/991,79019.03.2020US
62/991,81419.03.2020US
63/001,62430.03.2020US
63/001,63230.03.2020US
63/004,72903.04.2020US
63/006,96208.04.2020US
63/065,12913.08.2020US
63/065,13513.08.2020US
63/065,15213.08.2020US
63/065,16113.08.2020US
63/065,16313.08.2020US
63/073,15601.09.2020US
63/073,16101.09.2020US
63/081,05521.09.2020US
63/081,06221.09.2020US
63/083,38925.09.2020US
63/092,22915.10.2020US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) T CELL EPITOPES AND RELATED COMPOSITIONS USEFUL IN THE PREVENTION, DIAGNOSIS, AND TREATMENT OF COVID-19
(FR) ÉPITOPES DE LYMPHOCYTES T ET COMPOSITIONS ASSOCIÉES UTILES DANS LA PRÉVENTION, LE DIAGNOSTIC ET LE TRAITEMENT DE LA COVID-19
Abstract
(EN) The present disclosure generally relates to novel epitope-based compositions, including vaccines, against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and diseases caused by SARS-CoV-2, including the highly contagious coronavirus disease 2019 (which has been termed and may be referred to herein as "COVID-19", "2019-nCoV", or the "2019 novel coronavirus". The disclosure relates to immunogenic polypeptides and the uses thereof, particularly in vaccine compositions. The disclosure also relates to nucleic acids, vectors, and cells which express the polypeptides and the uses thereof. The polypeptides more specifically comprise an agretope predicted to be a ligand of HLA class I and/or HLA class II MHC molecules, as well as an epitope that is predicted to be recognized by T-cells in the context of MHC class I and/or class II molecules. The compositions are particularly suited to produce vaccines, particularly for vaccinating against SARS-CoV-2 infection and related diseases caused by SARS-CoV-2, including COVID-19.
(FR) La présente invention concerne de manière générale de nouvelles compositions à base d'épitopes, notamment des vaccins, contre le coronavirus du syndrome respiratoire aigu sévère 2 (SRAS-CoV-2) et les maladies provoquées par le SRAS-CoV-2, notamment la maladie à coronavirus 2019 hautement contagieuse (appelée et pouvant être dénommée ici "COVID-19 ", "2019-nCoV" ou "nouveau coronavirus 2019"). L'invention concerne des polypeptides immunogènes et leurs utilisations, en particulier dans des compositions vaccinales. L'invention concerne également des acides nucléiques, des vecteurs et des cellules qui expriment les polypeptides et leurs utilisations. Les polypeptides comprennent plus particulièrement un agrétope prédit comme étant un ligand de molécules CMH HLA de classe I et/ou HLA de classe II, ainsi qu'un épitope qui est prédit comme étant reconnu par des lymphocytes T dans le contexte de molécules CMH de classe I et/ou de classe II. Les compositions sont particulièrement appropriées pour produire des vaccins, en particulier pour la vaccination contre l'infection par le SRAS-CoV-2 et les maladies associées provoquées par le SRAS-CoV-2, notamment la COVID-19.
Latest bibliographic data on file with the International Bureau